Array Biopharma, now a wholly owned subsidiary of Pfizer
Quick facts
Phase 2 pipeline
- ARRY-438162, MEK inhibitor; oral · Oncology
Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer.
Phase 1 pipeline
- ARRY-142886, MEK inhibitor; oral · Oncology
MEK inhibitor - ARRY-300, MEK inhibitor; oral · Oncology
MEK inhibitor - ARRY-382, cFMS inhibitor; oral · Oncology
cFMS inhibitor - Capecitabine, 5-fluorouracil prodrug; oral
- Docetaxel, mitotic inhibitor; intravenous
- Paclitaxel, mitotic inhibitor; intravenous
- Prophylactic growth factors; subcutaneous
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: